Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif. — Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term...
Latest News
Niigata, Japan – A new Japanese nationwide study revealed that from 2006 to 2021, the number of patients with incident renal RRT due to RPGN increased, with an increase in the age-specific incidence of RRT due to RPGN in the older age groups (≥70 years old). Given the increasing trend...
LOS ANGELES, Calif. — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, today announced a clinical collaboration with Massachusetts General Hospital (MGH) to evaluate TRE-515 in up to six patients with advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease)...
Atlanta – In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the...
ROCKVILLE, Md. – GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan...
Paris, France – Testing for tumour DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows. This could allow doctors to target treatments more effectively to those who need it, and spare those patients for whom further treatment is unnecessary,...
LEXINGTON, Mass. — TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TRI-611, an investigational molecular glue degrader...
Birmingham, Alabama – Trikafta safely improved lung function and reduced exacerbations in people with cystic fibrosis (CF) who started treatment after age 40, a study found. Some participants no longer had Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA), bacteria that are major contributors to CF lung disease. “Overall, our study...
First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC Early Trend in Improvement in Overall Survival Observed FOSTER CITY, Calif. — Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk...
– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously...